Skip to main content
BioNote, Inc. logo

BioNote, Inc. — Investor Relations & Filings

Ticker · 377740 ISIN · KR7377740006 KO Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2023-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 377740

About BioNote, Inc.

https://www.bionote.com/

BioNote, Inc. is a company specializing in in-vitro diagnostics for the animal health industry. It develops, manufactures, and distributes a range of veterinary diagnostic products, including rapid test kits, ELISA kits, point-of-care (POC) analyzers, and biomarker tests. The company's portfolio is based on its research and development of core biological components like antigens and antibodies. Its products are designed for the detection and diagnosis of animal diseases, providing veterinarians with tools for immunochemical and quantitative analysis in clinical settings.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Bionote, Inc. It contains the meeting agenda, voting procedures (including electronic voting), director activity reports, and management information. This document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming Annual General Meeting (AGM) and to solicit their votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' category.
2023-03-14 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a correction (정정신고) to a previously filed 'Change in Sales or Profit/Loss Structure' report. It provides updated financial figures (revenue, operating profit, net income) for the fiscal year 2022 due to accounting adjustments. Since this is a formal regulatory announcement of financial results and their subsequent correction, it falls under the 'Earnings Release' category as it details the key financial highlights and performance metrics for the period. FY 2022
2023-03-13 Korean
[기재정정]연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a regulatory filing from Bionote regarding a correction (amendment) to previously announced preliminary financial results. It details specific changes to operating profit, net income, and other financial metrics due to accounting adjustments. As it is an initial announcement of financial performance (even if a correction), it falls under the Earnings Release category. Q4 2022
2023-03-13 Korean
결산실적공시예고(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Bionote regarding the scheduled date for the release of their annual financial results. It does not contain the actual financial statements, but rather serves as a notification of when the report will be published. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2023-02-28 Korean
기업설명회(IR)개최(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (690 characters) regarding the scheduling of an Investor Relations (IR) meeting. It provides the date, time, and purpose of the meeting (2022 financial results) and explicitly states that the actual IR presentation materials will be posted on the company website later. Following the 'Menu vs Meal' rule, this is an announcement of an event/report rather than the report itself, fitting the criteria for a Report Publication Announcement (RPA).
2023-02-28 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (BioNote) announcing a significant change in financial results (revenue/profit structure change of 30% or more). This is a standard preliminary earnings announcement required by the Korea Exchange (KRX) when there is a material variance in financial performance compared to the previous period. It provides key financial highlights (revenue, operating profit, net income) and explicitly states these are preliminary figures subject to audit. This fits the definition of an Earnings Release (ER). FY 2022
2023-02-28 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.